ストックスクリーナーアプリを入手
4.66
1.53%
0.07
プレマーケット:
4.66
Abcellera Biologics Inc (ABCL) 最新ニュース
MSN Money - MSN
AbCellera Biologics Stock (ABCL) Opinions on Earnings and ABCL635 Phase 1 Data - Quiver Quantitative
Cantor Fitzgerald Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $7 - Moomoo
JonesResearch Reiterates Buy on AbCellera Biologics (ABCL) - Insider Monkey
5 Best Healthcare AI Stocks to Buy According to Analysts - Insider Monkey
A Look At AbCellera Biologics (ABCL) Valuation As It Prepares ABCL635 Phase 1 Interim Update - Yahoo Finance
AbCellera Biologics Among 3 Promising Penny Stocks - Yahoo Finance
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7 - Moomoo
AbCellera Biologics | ARS: Annual Report to Security Holders - Moomoo
[ARS] AbCellera Biologics Inc. SEC Filing - Stock Titan
AbCellera Biologics (NASDAQ:ABCL) Shares Down 7.6%Time to Sell? - MarketBeat
AbCellera (NASDAQ: ABCL) details 2026 vote on directors, auditor and Say-on-Pay - Stock Titan
AbCellera Biologics | DEFA14A: Others - Moomoo
AbCellera Biologics | DEF 14A: Definitive information statements - Moomoo
Jones Trading initiates coverage of AbCellera Biologics (ABCL) with buy recommendation - MSN
Leerink Partners Downgrades AbCellera Biologics (ABCL) - MSN
AbCellera Biologics Pivots to In-House Pipeline, Teases Q3 Phase II Data for ABCL635 Hot Flashes - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price & News - The Motley Fool Canada
BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7 - Moomoo
JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $11 - Moomoo
AbCellera (ABCL) Positioned Favorably Ahead of Phase 1 Update - GuruFocus
ABCL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AbCellera Biologics (ABCL) Is Up 6.8% After Announcing First Human Data Timeline For ABCL635 - simplywall.st
ABCL: Lead antibody for menopausal hot flashes nears pivotal phase II data, aiming for market differentiation - TradingView
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - BioSpace
AbCellera to share Phase 1 data for menopause drug on May 11 - Investing.com Australia
JonesResearch Initiates Coverage of AbCellera Biologics Inc. (ABCL) - Insider Monkey
AbCellera to share Phase 1 data for menopause drug on May 11 By Investing.com - Investing.com South Africa
Press Release: AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - Moomoo
10 Stocks Under $5 with Huge Upside Potential - Insider Monkey
AbCellera Biologics Inc. (ABCL): A bull case theory - MSN
AbCellera Biologics (ABCL) Committed to Leverage Differentiated Technology for Drug Discovery - MSN
AbCellera (ABCL): Among the stocks that could 10x over the next 5 years - MSN
AbCellera Biologics Inc. (ABCL) - DirectorsTalk Interviews
Truist reiterates Buy on AbCellera stock, eyes 2H26 data readout By Investing.com - Investing.com Canada
Truist reiterates Buy on AbCellera stock ahead of 2H26 data - Investing.com
Truist reiterates Buy on AbCellera stock ahead of 2H26 data By Investing.com - Investing.com Canada
Truist reiterates Buy on AbCellera stock, eyes 2H26 data readout - Investing.com
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating - 富途牛牛
Biotech Penny Stocks Rally OABI ABCL PACB 2026 - Gotrade
Is Jones Trading’s New Coverage of AbCellera (ABCL) Reframing Its Clinical-Stage Platform Narrative? - Yahoo Finance
Is AbCellera Biologics Inc affected by consumer sentimentWall Street Watch & Free High Return Stock Watch Alerts - baoquankhu1.vn
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):